login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PDS BIOTECHNOLOGY CORP (PDSB) Stock News
USA
-
Nasdaq
- NASDAQ:PDSB -
US70465T1079
-
Common Stock
0.7554
USD
0 (-0.09%)
Last: 11/21/2025, 8:00:01 PM
0.7401
USD
-0.02 (-2.03%)
After Hours:
11/21/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PDSB Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market
10 days ago - By: PDS Biotechnology Corporation
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
12 days ago - By: Benzinga
- Mentions:
AIM
STXS
PRPH
LUCY
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 days ago - By: PDS Biotechnology Corporation
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
13 days ago - By: PDS Biotechnology Corporation
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
17 days ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
24 days ago - By: Stocktwits
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
24 days ago - By: Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
25 days ago - By: PDS Biotechnology Corporation
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
2 months ago - By: PDS Biotechnology Corporation
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
3 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
3 months ago - By: The Motley Fool
PDSB Loss Improves as Costs Drop
3 months ago - By: PDS Biotechnology Corporation
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
3 months ago - By: Benzinga
Insights into PDS Biotechnology's Upcoming Earnings
4 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
6 months ago - By: PDS Biotechnology Corporation
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
6 months ago - By: Zacks Investment Research
- Mentions:
INTU
ADP
PWR
FAST
...
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus
6 months ago - By: PDS Biotechnology Corporation
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
6 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
6 months ago - By: Yahoo Finance
- Mentions:
IBRX
COMM
HD
CAVA
...
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
6 months ago - By: PDS Biotechnology Corporation
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
6 months ago - By: PDS Biotechnology Corporation
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
7 months ago - By: PDS Biotechnology Corporation
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
7 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
8 months ago - By: PDS Biotechnology Corporation
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
8 months ago - By: Stocktwits
- Mentions:
VTI
VXF
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish
8 months ago - By: PDS Biotechnology Corporation
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Please enable JavaScript to continue using this application.